Home・Список акций・Royalty Pharma PLC (Class A)

Royalty Pharma PLC (Class A)

Закрыт

СекторЗдравоохранение

58.55 -1.1

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

57.86

Макс.

59.54

Ключевые показатели
By Trading Economics
Доход	-589M -295M
Продажи	44M 674M
P/E Средняя по отрасли	30.511 57.002
Прибыль на акцию	1.32
Дивидендная доходность	1.6
Рентабельность продаж	-43.713
Сотрудники	100
EBITDA	-387M 176M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+10.89% upside

Дивиденды
By Acuity
Дивидендная доходность Средняя по отрасли	1.60% 2.22%
Следующий отчет о доходах	4 нояб. 2026 г.
Дата следующей выплаты дивидендов	10 сент. 2026 г.
Следующая эксдивидендная дата	14 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	577M 33B
Предыдущая цена открытия	59.65
Предыдущая цена закрытия	58.55

Royalty Pharma PLC (Class A) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

13 авг. 2026 г., 20:02 UTC

Social Media

Royalty Pharma PLC shares are lower amid a $100 million royalty agreement with Zealand Pharma for rusfertide rights, reflecting unusual trading activity.

12 авг. 2026 г., 20:01 UTC

Royalty Pharma PLC shares are higher today, supported by a broader market trend of gains since Tuesday. The stock is seeing unusually high trading volume.

11 авг. 2026 г., 19:56 UTC

Royalty Pharma PLC shares are trading higher, reaching a session high earlier today. No specific news was identified to explain the price movement.

10 авг. 2026 г., 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting notable strength and unusual activity since Monday's close, with no specific news identified.

7 авг. 2026 г., 23:41 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting notable gains since Friday's close amid a shift toward a dovish monetary policy outlook.

6 авг. 2026 г., 23:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, moving above Thursday's close, despite remaining below the 20-day moving average.

5 авг. 2026 г., 19:31 UTC

News

Royalty Pharma PLC raised its full-year guidance for Portfolio Receipts to $3.4 billion to $3.5 billion, contributing to a higher trading session.

4 авг. 2026 г., 19:26 UTC

Royalty Pharma PLC shares are higher today, rebounding after earlier pulling back from a session high. The stock has fluctuated within a routine range.

3 авг. 2026 г., 23:46 UTC

Royalty Pharma PLC shares are near unchanged in after-market trading, reflecting minimal movement since Monday's close and remaining below the 20-day moving average.

1 авг. 2026 г., 00:03 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline over the past four sessions. No specific news was identified to explain the move.

31 июл. 2026 г., 23:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting broader market trends despite some gains in mega-cap stocks. The stock remains below its 20-day moving average.

30 июл. 2026 г., 22:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting strong demand and trading above its 20-day moving average. No specific news was identified.

29 июл. 2026 г., 19:27 UTC

Royalty Pharma PLC shares are lower today, reflecting a pullback since Tuesday's close amid rising oil prices and inflation concerns.

28 июл. 2026 г., 23:46 UTC

Royalty Pharma PLC shares are lower in after-market trading, reflecting broader market declines amid concerns over technology sector dynamics.

27 июл. 2026 г., 16:46 UTC

Royalty Pharma PLC shares are advancing during Monday's session. Broader market gains are supported by a notable decline in oil prices amid easing geopolitical tensions.

24 июл. 2026 г., 22:21 UTC

In after-market trading, Royalty Pharma PLC is trading higher, nearing the upper end of its one-month range after recovering from an early low.

22 июл. 2026 г., 19:11 UTC

News

Event

Royalty Pharma acquires a royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront payment. Shares are trading roughly flat.

21 июл. 2026 г., 17:51 UTC

Royalty Pharma PLC shares are higher today, tracking broader market gains, with unusually high trading volume noted. No specific news was identified for the movement.

20 июл. 2026 г., 19:21 UTC

Royalty Pharma PLC shares are lower as the Pharmaceuticals sector faces downward pressure, with unusually high trading volume noted today.

Сравнение c конкурентами

Изменение цены

Royalty Pharma PLC (Class A) Прогноз

Целевая цена

By TipRanks

10.89% рост

Прогноз на 12 месяцев

Средняя 65.67 USD 10.89%

Максимум 70 USD

Минимум 62 USD

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Royalty Pharma PLC (Class A) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

7 ratings

Покупка

Удержание

Продажа

Основано на мнении 7 аналитиков, присваивавших рейтинги акциям Royalty Pharma PLC (Class A) – Данные за последние 3 месяца.

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.